Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Consent Decree Remains Likely for Hospira as Negative Inspections Continue: Analyst

Drug Industry Daily

Nov. 8, 2012 | Vol. 11 No. 220

Consent Decree Remains Likely for Hospira as Negative Inspections Continue: Analyst

Hospira continues to remain at risk for a consent decree as negative manufacturing updates, additional form 483 observations and product recalls pile up, one analyst says.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Rise in Global Trial Recruitment Raises Ethics, Compliance Concerns in EU Novartis 483 Highlights Rocky Remediation at Nebraska Plant Hamburg: Conditions Observed During Compounding Pharmacy Inspections Were "Startling"Hamburg: Conditions Observed During Compounding Pharmacy Inspections Were "Startling"

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.